Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual

William E. Soares, Donna Wilson, Michael S. Gordon, Joshua Lee, Edward V. Nunes, Charles P. O'Brien, Milvin Shroff, Peter D. Friedmann

Research output: Contribution to journalArticle

Abstract

Background: Criminal justice involved (CJS) populations with opioid use disorder (OUD) have high rates of relapse, future arrests, and death upon release. While medication for OUD (MOUD) reduces opioid relapse, concerns regarding diversion and stigma limit treatment in CJS populations. Extended release naltrexone (XR-NTX), as an opioid antagonist, may be more acceptable to CJS administrators. However, the impact of XR-NTX on criminal recidivism remains unknown. Methods: Arrest data from a published randomized trial comparing XR-NTX to treatment as usual (TAU) was captured by self-report and official state arrest records. Comparisons of future arrests, time to first arrest and total number of arrests were performed using chi square tests and multivariable generalized regression models. Secondary outcomes explored differences in arrests by type and severity of crime, use of opioid and other drugs, and study phase. Results: Of 308 participants randomized, 300 had arrest data. The incidence of arrests did not differ between XR-NTX (47.6%) and TAU (42.5%) participants. (ChiSq p = 0.37). Additionally, there was no significant difference in time to first arrest (adjusted HR 1.35, CI 0.96–1.89) and number of arrests per participant (adjusted IR 1.33, CI 0.78–2.27). Controlling for gender, age, previous criminal activity, and use of non-opioid drugs, logistic regression demonstrated no significant difference in incidence of arrests between groups (adjusted OR 1.38, 95% CI 0.85–2.22). Conclusions: We detected no significant difference in arrests between CJS participants with OUD randomized to XR-NTX or TAU. Despite its efficacy in reducing opioid use, XR-NTX alone may be insufficient to reduce criminal recidivism.

Original languageEnglish (US)
Pages (from-to)482-486
Number of pages5
JournalDrug and Alcohol Dependence
Volume194
DOIs
StatePublished - Jan 1 2019

Fingerprint

Naltrexone
Criminal Law
Opioid Analgesics
Incidence
Therapeutics
Recurrence
Narcotic Antagonists
Crime
Chi-Square Distribution
Administrative Personnel
Pharmaceutical Preparations
Self Report
Population
Logistics
Logistic Models

Keywords

  • Criminal recidivism
  • Extended release naltrexone
  • Opioid use disorder

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. / Soares, William E.; Wilson, Donna; Gordon, Michael S.; Lee, Joshua; Nunes, Edward V.; O'Brien, Charles P.; Shroff, Milvin; Friedmann, Peter D.

In: Drug and Alcohol Dependence, Vol. 194, 01.01.2019, p. 482-486.

Research output: Contribution to journalArticle

Soares, William E. ; Wilson, Donna ; Gordon, Michael S. ; Lee, Joshua ; Nunes, Edward V. ; O'Brien, Charles P. ; Shroff, Milvin ; Friedmann, Peter D. / Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. In: Drug and Alcohol Dependence. 2019 ; Vol. 194. pp. 482-486.
@article{7e8d8c2c3da3403db9c1c2e8374e1482,
title = "Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual",
abstract = "Background: Criminal justice involved (CJS) populations with opioid use disorder (OUD) have high rates of relapse, future arrests, and death upon release. While medication for OUD (MOUD) reduces opioid relapse, concerns regarding diversion and stigma limit treatment in CJS populations. Extended release naltrexone (XR-NTX), as an opioid antagonist, may be more acceptable to CJS administrators. However, the impact of XR-NTX on criminal recidivism remains unknown. Methods: Arrest data from a published randomized trial comparing XR-NTX to treatment as usual (TAU) was captured by self-report and official state arrest records. Comparisons of future arrests, time to first arrest and total number of arrests were performed using chi square tests and multivariable generalized regression models. Secondary outcomes explored differences in arrests by type and severity of crime, use of opioid and other drugs, and study phase. Results: Of 308 participants randomized, 300 had arrest data. The incidence of arrests did not differ between XR-NTX (47.6{\%}) and TAU (42.5{\%}) participants. (ChiSq p = 0.37). Additionally, there was no significant difference in time to first arrest (adjusted HR 1.35, CI 0.96–1.89) and number of arrests per participant (adjusted IR 1.33, CI 0.78–2.27). Controlling for gender, age, previous criminal activity, and use of non-opioid drugs, logistic regression demonstrated no significant difference in incidence of arrests between groups (adjusted OR 1.38, 95{\%} CI 0.85–2.22). Conclusions: We detected no significant difference in arrests between CJS participants with OUD randomized to XR-NTX or TAU. Despite its efficacy in reducing opioid use, XR-NTX alone may be insufficient to reduce criminal recidivism.",
keywords = "Criminal recidivism, Extended release naltrexone, Opioid use disorder",
author = "Soares, {William E.} and Donna Wilson and Gordon, {Michael S.} and Joshua Lee and Nunes, {Edward V.} and O'Brien, {Charles P.} and Milvin Shroff and Friedmann, {Peter D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.drugalcdep.2018.10.035",
language = "English (US)",
volume = "194",
pages = "482--486",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual

AU - Soares, William E.

AU - Wilson, Donna

AU - Gordon, Michael S.

AU - Lee, Joshua

AU - Nunes, Edward V.

AU - O'Brien, Charles P.

AU - Shroff, Milvin

AU - Friedmann, Peter D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Criminal justice involved (CJS) populations with opioid use disorder (OUD) have high rates of relapse, future arrests, and death upon release. While medication for OUD (MOUD) reduces opioid relapse, concerns regarding diversion and stigma limit treatment in CJS populations. Extended release naltrexone (XR-NTX), as an opioid antagonist, may be more acceptable to CJS administrators. However, the impact of XR-NTX on criminal recidivism remains unknown. Methods: Arrest data from a published randomized trial comparing XR-NTX to treatment as usual (TAU) was captured by self-report and official state arrest records. Comparisons of future arrests, time to first arrest and total number of arrests were performed using chi square tests and multivariable generalized regression models. Secondary outcomes explored differences in arrests by type and severity of crime, use of opioid and other drugs, and study phase. Results: Of 308 participants randomized, 300 had arrest data. The incidence of arrests did not differ between XR-NTX (47.6%) and TAU (42.5%) participants. (ChiSq p = 0.37). Additionally, there was no significant difference in time to first arrest (adjusted HR 1.35, CI 0.96–1.89) and number of arrests per participant (adjusted IR 1.33, CI 0.78–2.27). Controlling for gender, age, previous criminal activity, and use of non-opioid drugs, logistic regression demonstrated no significant difference in incidence of arrests between groups (adjusted OR 1.38, 95% CI 0.85–2.22). Conclusions: We detected no significant difference in arrests between CJS participants with OUD randomized to XR-NTX or TAU. Despite its efficacy in reducing opioid use, XR-NTX alone may be insufficient to reduce criminal recidivism.

AB - Background: Criminal justice involved (CJS) populations with opioid use disorder (OUD) have high rates of relapse, future arrests, and death upon release. While medication for OUD (MOUD) reduces opioid relapse, concerns regarding diversion and stigma limit treatment in CJS populations. Extended release naltrexone (XR-NTX), as an opioid antagonist, may be more acceptable to CJS administrators. However, the impact of XR-NTX on criminal recidivism remains unknown. Methods: Arrest data from a published randomized trial comparing XR-NTX to treatment as usual (TAU) was captured by self-report and official state arrest records. Comparisons of future arrests, time to first arrest and total number of arrests were performed using chi square tests and multivariable generalized regression models. Secondary outcomes explored differences in arrests by type and severity of crime, use of opioid and other drugs, and study phase. Results: Of 308 participants randomized, 300 had arrest data. The incidence of arrests did not differ between XR-NTX (47.6%) and TAU (42.5%) participants. (ChiSq p = 0.37). Additionally, there was no significant difference in time to first arrest (adjusted HR 1.35, CI 0.96–1.89) and number of arrests per participant (adjusted IR 1.33, CI 0.78–2.27). Controlling for gender, age, previous criminal activity, and use of non-opioid drugs, logistic regression demonstrated no significant difference in incidence of arrests between groups (adjusted OR 1.38, 95% CI 0.85–2.22). Conclusions: We detected no significant difference in arrests between CJS participants with OUD randomized to XR-NTX or TAU. Despite its efficacy in reducing opioid use, XR-NTX alone may be insufficient to reduce criminal recidivism.

KW - Criminal recidivism

KW - Extended release naltrexone

KW - Opioid use disorder

UR - http://www.scopus.com/inward/record.url?scp=85057772772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057772772&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2018.10.035

DO - 10.1016/j.drugalcdep.2018.10.035

M3 - Article

C2 - 30522048

AN - SCOPUS:85057772772

VL - 194

SP - 482

EP - 486

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

ER -